| Abstrakt: |
A recent study conducted at Chongqing Medical University in the People's Republic of China analyzed trends in neoadjuvant therapy (NAT) for pancreatic cancer over the past 20 years. The research, funded by the Joint project of Chongqing Health Commission and Science and Technology Bureau, identified hotspots in current research, such as the optimal NAT regimen and management of complications. The study highlighted the increasing attention NAT has received in the field of pancreatic cancer, emphasizing the need for greater collaboration between countries and more multicenter randomized clinical trials. [Extracted from the article] |
